Previous close | 4.45 |
Open | 5.00 |
Bid | 5.26 x 600 |
Ask | 5.29 x 1000 |
Day's range | 4.75 - 5.47 |
52-week range | 4.03 - 8.96 |
Volume | |
Avg. volume | 3,289,486 |
Market cap | 1.087B |
Beta (5Y monthly) | 1.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.18 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 13.82 |
Significant Growth in ORLADEYO Sales and Strategic Pipeline Advancements Mark the Quarter
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials— RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and pr